General Medicine
Rheumatologic Management
Rheumatologic management for MBBS: synovial fluid analysis, disease-modifying and biologic therapy, gout treatment and monitoring, mapped to NMC codes IM7.15 to IM7.27.
MedNext Academy | 3 min read
Rheumatologic Management
Rheumatologic management for MBBS: synovial fluid analysis, disease-modifying and biologic therapy, gout treatment and monitoring, mapped to NMC codes IM7.15 to IM7.27.
This chapter covers the treatment of rheumatologic disease, from interpreting synovial fluid and radiographs to the graded use of disease-modifying and biologic therapy. It sets out the management of gout and crystal arthropathy, corticosteroid safety, pre-biologic screening and long-term monitoring.
High-yield: Rheumatologic Management
- Synovial fluid analysis separates non-inflammatory, inflammatory, septic and haemorrhagic joint effusions by cell count and crystals.
- A synovial white cell count above 50,000 per cubic millimetre strongly suggests septic arthritis.
- Methotrexate is the anchor disease-modifying drug for rheumatoid arthritis and needs folic acid supplementation.
- Disease-modifying antirheumatic drugs should be started early to prevent irreversible joint damage.
- Biologic agents such as tumour necrosis factor inhibitors are used when conventional agents fail, after excluding latent tuberculosis.
- Acute gout is treated with a non-steroidal anti-inflammatory drug, colchicine or a corticosteroid.
- Urate-lowering therapy with allopurinol is preventive and should not be started or stopped during an acute attack.
- Allopurinol is up-titrated to a target serum urate below 6 milligrams per decilitre.
- Corticosteroids control disease quickly but their long-term use needs monitoring for osteoporosis, infection and glucose intolerance.
- Screening for latent tuberculosis and hepatitis is mandatory before starting biologic therapy in India.
- Non-steroidal anti-inflammatory drugs relieve symptoms but do not modify the course of rheumatoid arthritis.
- Regular monitoring of blood counts, liver and renal function is required with disease-modifying therapy.
- Joint aspiration relieves symptoms and provides fluid for diagnosis in an acutely swollen joint.
- Patient education, adherence support and quality-of-life assessment are integral to rheumatologic care.
- Early specialist referral improves outcomes in aggressive or refractory inflammatory arthritis.
Rheumatologic treatment principles
- **Anchor drug:** Methotrexate with folic acid is first-line disease-modifying therapy in rheumatoid arthritis.
- **Start early:** Disease-modifying drugs are begun early to prevent irreversible joint damage.
- **Gout:** Treat the attack with an NSAID, colchicine or steroid; lower urate with allopurinol between attacks.
- **Before biologics:** Screen for latent tuberculosis and hepatitis and monitor blood counts and liver function.
NMC competencies in this chapter
- **IM7.15:** Interpreting blood counts and autoimmune tests
- **IM7.16:** Indications for arthrocentesis
- **IM7.19:** Treatment plans for rheumatologic diseases
- **IM7.20:** Medications for relief of joint pain
- **IM7.21:** Preventive therapy for crystal arthropathies
- **IM7.22:** Treatment options for systemic rheumatologic conditions
- **IM7.23:** Basis for biologic and disease-modifying therapy
- **IM7.25:** Follow-up and monitoring plans
Frequently Asked Questions
What is the first-line disease-modifying drug in rheumatoid arthritis?
Methotrexate is the anchor disease-modifying antirheumatic drug and is given with folic acid supplementation to reduce adverse effects; it should be started early.
How is acute gout managed versus chronic gout?
The acute attack is treated with an NSAID, colchicine or corticosteroid, while urate-lowering therapy such as allopurinol is used between attacks and not started during an acute flare.
What must be checked before starting biologic therapy?
Latent tuberculosis and hepatitis B and C must be screened for before starting biologics such as tumour necrosis factor inhibitors, because they can reactivate these infections.
How does this chapter help for NEET-PG?
Synovial fluid thresholds, the role of methotrexate, allopurinol targets and pre-biologic screening are recurring exam themes that map directly to questions.
Continue reading
MBBSAll General Medicine chapters
Continue through the General Medicine chapter map.
Continue studying General Medicine
Explore clinician-written learning resources, structured revision and practice across the MedNext platform.
Open in the MedNext appSee plans